During the last three years Dyadic (Dyadic International, Inc.; NASDAQ: DYAI) and VTT have developed a more efficient and lower cost alternative to produce therapeutic proteins, vaccines and valuable metabolites. The method is based on exploiting the Thermothelomyces heterothallica C1 fungal strain. The partners are now developing a new production method for a SARS-CoV-2 coronavirus vaccine.
Read the full article: https://www.vttresearch.com/en/news-and-ideas/dyadic-and-vtt-are-developing-efficient-new-production-method-covid19-vaccines
More information:
VTT Technical Research Centre of Finland Ltd Christopher Landowski, Research Team Leader tel. +358 40 482 0856, christopher.landowski@vtt.fi
Markku Saloheimo, Senior Principal Scientist tel. +358 405760892, markku.saloheimo@vtt.fi
Dyadic International, Inc. Mark A. Emalfarb, Chief Executive Officer Tel. +1 (561) 743-8333, memalfarb@dyadic.com